Health
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...
2024-01-25 18:00
1671
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the interi...
2024-01-25 16:56
1444
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients - WuXiaADCC PLU...
2024-01-25 08:30
1468
Wellysis Goes Global with ECG Monitor 'S-Patch', Enters US and Indian Markets
SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Digital healthcare innovator Wellysis is making waves in the global market with its revolutionary electrocardiogram (ECG) monitoring solution, 'S-Patch,' securing strategic partnerships and distribution deals to propel its entry into the lucrative...
2024-01-24 22:00
1576
WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit
CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements,Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit inBerlin, Germany. Renowned for her pivotal role in mRNA research, Dr.Xiangrong Song, co-founder and CEO o...
2024-01-24 21:32
1400
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11β-HSD1, with high levels of target occupancy at doses as low as 5 mg SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tom...
2024-01-24 21:30
1473
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI
* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was observed in 3 out of 8 patients who were previously treated by immunotherapy SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in...
2024-01-24 21:00
1432
PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions
Eli Lilly and Company, Santec Holdings Corporation participated in the round TOKYO, Jan. 24, 2024 /PRNewswire/ -- TOKYO, Jan. 24, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protei...
2024-01-24 16:00
1271
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 23, 2024 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) ofthe United States to init...
2024-01-24 12:40
1416
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
SHANGHAI and INCHEON, South Korea, Jan. 23, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical...
2024-01-24 11:37
1235
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
* Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA® * The clinical trial aims to enroll a total of 67 patients across four institutions inAustralia DAEJEON, South Korea, Jan. 23, 2024 /PRNewswire/ ...
2024-01-24 10:01
1159
Datasea Pre-Announces First Half 2024 Revenue of $18.2 Million, a 1,037.5% Year-Over-Year Increase
BEIJING, Jan. 23, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology inChina pre-announced that its revenue...
2024-01-23 22:35
3063
Rhino Rescue Speeds into the Future of First-Aid Supplies with New Year Resolutions for 2024
Propelling Lifesaving Measures with User-friendly Innovations in 2024
SHANGHAI, Jan. 23, 2024 /PRNewswire/ -- As the New Year unfolds, Rhino Rescue
2024-01-23 22:15
1531
Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mi...
2024-01-23 21:00
2985
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. "We are all delighted to see CBL-514 show...
2024-01-23 18:35
1132
Baird Medical Performs First Thyroid Microwave Ablation Procedure in the United States
FRISCO, Texas, Jan. 23, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced that it has performed its first thyroid MWA procedure inthe United...
2024-01-23 18:00
1202
European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)
YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, designed for Sanfilippo Syndrome...
2024-01-23 11:53
1360
36,000 units of MAIDeSITe Electric Floor Lift have been sold on Amazon
HANGZHOU, China, Jan. 22, 2024 /PRNewswire/ --
The MAIDeSITe Electric Floor Lift
2024-01-23 10:59
1040
UHS deploys Cutting-Edge Robotic Cleaning Technology developed by CenoBots
AUSTIN, Texas, Jan. 22, 2024 /PRNewswire/ -- CenoBots is excited to announce its partnership with UHS fromSan Antonio, a valued hospital system partner, for deploying cleaning robots. The deployment is also being carried out in collaboration with Hellogard Robotics. This collaboration serves as a...
2024-01-22 21:00
1127
NK CellTech Announces FDA Clearance for Clinical Trial of NK010
SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- On January 17, 2024, NK CellTech Co., Ltd. (NK CellTech), a leading biotech company focused on the development of NK cellular therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of NK010, the non-genetically modified ...
2024-01-22 20:10
1351
Week's Top Stories
Most Reposted
Co-creating a Digital and Intelligent World, H3C Digital Tour 2024 Concludes Successfully
[Picked up by 298 media titles]
2024-07-04 12:02
Yidu Tech Announces Annual Results for FY 2024: Existing Business Achieves First Full-Year Profit on Adjusted EBITDA
[Picked up by 291 media titles]
2024-07-01 09:05
AI and Sustainability in Advanced Manufacturing to take Centre Stage at Industrial Transformation ASIA-PACIFIC (ITAP) 2024
[Picked up by 285 media titles]
2024-07-03 15:51
National Cancer Society Malaysia and Gene Solutions Forge Partnership to Expand Multi-Cancer Early Detection Awareness and Access
[Picked up by 278 media titles]
2024-07-01 12:55
The Global Multimedia Deepfake Detection Challenge 2024 Officially Announced with Over $130,000 in Prizes
[Picked up by 277 media titles]
2024-07-01 16:47
Most Read
Yidu Tech Announces Annual Results for FY 2024: Existing Business Achieves First Full-Year Profit on Adjusted EBITDA
2024-07-01 09:05
17274
National Cancer Society Malaysia and Gene Solutions Forge Partnership to Expand Multi-Cancer Early Detection Awareness and Access
2024-07-01 12:55
12033
Transforming Healthcare with AI: YiduTech's Gong Rujing at Summer Davos
2024-07-01 10:17
10271
